9049. Tamsulosin
Nomenclature
CAS number: 106133-20-4
5-[(2R)-2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide; amsulosin. C20H28N2O5S; mol wt 408.51.
C 58.80%, H 6.91%, N 6.86%, O 19.58%, S 7.85%.
Description and references
Specific α1-adrenoceptor antagonist. Prepn: K. Imai et al., EP 34432; eidem, US 4703063 (1981, 1987 both to Yamanouchi). Comparative pharmacology of enantiomers and racemate: K. Honda et al., Arch. Pharmacol. 336, 295 (1987). HPLC determn in plasma: Y. Soeishi et al., J. Chromatogr. 533, 291 (1990). Clinical trials in benign prostatic hypertrophy: K. Kawabe et al., J. Urol. 144, 908 (1990); P. Abrams et al., Br. J. Urol. 76, 325 (1995). Review of pharmacology and clinical experience in urological disorders: M. C. Michel, J. J. de la Rosette, Expert Opin. Pharmacother. 5, 151-160 (2004).
Derivative
Hydrochloride.Nomenclature
CAS number: 106463-17-6
LY-253351; YM-12617-1; YM-617; Flomax (Astellas); Flomaxtra (Astellas); Harnal (Astellas); Omnic (Astellas); Pradif (Boehringer, Ing.). C20H28N2O5S.HCl; mol wt 444.97.
C 53.98%, H 6.57%, N 6.30%, O 17.98%, S 7.21%, Cl 7.97%.
Properties
White crystals. mp 228-230° (dec). [α]D24 4.0° (c = 0.35 in methanol). Sparingly sol in water, methanol; slightly sol in glacial acetic acid, ethanol. Practically insol in ether.Therapeutic Category
In treatment of benign prostatic hypertrophy.
Keywords
α-Adrenergic Blocker; Antiprostatic Hypertrophy